Why is Akums Drugs falling/rising?

As of 22-Sep, Akums Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 474.10, reflecting a decrease of 2.5 or 0.52%. The stock has shown a trend reversal after two consecutive days of gains, and it has outperformed its sector by 0.56% today. However, the stock's performance over the past month has been negative, with a return of -1.57%, and it has significantly underperformed over the past year, with a return of -44.14%. The company's low debt-to-equity ratio and attractive valuation, indicated by a return on equity of 10.6 and a price-to-book value of 2.5, contrast with its poor long-term growth, as net sales have only grown at an annual rate of 6.10%. Additionally, the recent decline in investor participation, with a 60.33% drop in delivery volume, suggests waning interest in the stock.
In the broader market context, Akums Drugs has outperformed the Sensex in the short term, with a 1-week return of +0.72% compared to the benchmark's +0.46%. However, the stock's long-term performance has been disappointing, underperforming the BSE500 over the last three years, one year, and three months. The company's flat results in the most recent quarter, including a significant drop in profit after tax and the lowest operating profit to interest ratio, further contribute to the negative sentiment surrounding the stock. Overall, while there are some positive indicators, the combination of poor long-term growth prospects and recent declines in investor interest is leading to the stock's current downward movement.